Decoy Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Decoy Therapeutics Inc.
- Former names
- Salarius Pharmaceuticals, Inc. Flex Pharma, Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Houston
- Headquarters state / province
- Texas
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- DCOY
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001615219
- EIN
- 46-5087339
Board of directors
-
Arnold C. Hanish · DirectorSince 2023
-
Bruce J. McCreedy Jr. · DirectorSince 2023
-
David J. Arthur · Director · Chief Executive OfficerSince 2023
-
Jonathan I. Lieber · DirectorSince 2023
-
Patricia G. Gauthier · DirectorSince 2026
-
Paul Lammers · DirectorSince 2023
-
Tess Burleson · DirectorSince 2023
-
William K. McVicar · DirectorSince 2023
Chief executives
David J. Arthur
· Chief Executive Officer
Dates unknown
Director election results
Annual meeting of December 31, 2025. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
92.3%
-
93.5%
Board connections
1 of this board's directors also sit on 1 other board.
- via Arnold C. Hanish
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $19,750
- 2 purchases by 2 insiders
- Sold, last 12 months
- $17
- 2 sales by 1 insider
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 31, 2026 | Tess Burleson Director | Grant or award | +2,000 | — | — |
| Aug 31, 2026 | Jonathan I. Lieber Director | Grant or award | +2,000 | — | — |
| Aug 31, 2026 | PIERCE FREDERICK II Officer (Chief Executive Officer) | Grant or award | +33,455 | — | — |
| Aug 31, 2026 | Arnold C. Hanish Director | Grant or award | +3,000 | — | — |
| Aug 31, 2026 | Rosenblum Mark J Officer (Chief Financial Officer) | Grant or award | +9,682 | — | — |
| Aug 31, 2026 | Paul Lammers Director | Grant or award | +2,000 | — | — |
| Aug 31, 2026 | William K. McVicar Director | Grant or award | +3,000 | — | — |
| Aug 31, 2026 | Hibner Barbara Louise Officer (Chief Scientific Officer) | Grant or award | +4,216 | — | — |
| Aug 31, 2026 | Marschel Peter Klaus Officer (Chief Business Officer) | Grant or award | +3,900 | — | — |
| Aug 31, 2026 | Patricia G. Gauthier Director | Grant or award | +2,000 | — | — |
| Dec 30, 2025 | Arnold C. Hanish Director | Open-market sale | −15 | $0.64 | $10 |
| Dec 30, 2025 | Arnold C. Hanish Director | Open-market sale | −12 | $0.64 | $8 |
| Nov 20, 2025 | Arnold C. Hanish Director | Open-market purchase | +5,000 | $0.75 | $3,750 |
| Nov 20, 2025 | Rosenblum Mark J Officer (Exec VP Finance, CFO) | Open-market purchase | +20,000 | $0.80 | $16,000 |
| Feb 13, 2023 | Rosenblum Mark J Officer (Exec VP Finance, CFO) | Grant or award | +6,432 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.